emClinical & Translational Immunology/em | ASI Journal | Wiley Online Library
“In conclusion, our findings demonstrate that immunomodulatory changes in both myeloid and lymphoid cells can persist for up to 17 months following COVID-19, even in individuals who experienced only MILD illness.”m